Needham analyst Serge Belanger reiterated a Buy rating on Heron Therapeutics (HRTX – Research Report) today and set a price target of $7.00. The company’s shares closed yesterday at $2.55.
Belanger covers the Healthcare sector, focusing on stocks such as Esperion, Cytokinetics, and KalVista Pharmaceuticals. According to TipRanks, Belanger has an average return of -0.2% and a 42.60% success rate on recommended stocks.
Heron Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $8.50.
See Insiders’ Hot Stocks on TipRanks >>
Based on Heron Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $30.03 million and a GAAP net loss of $19.87 million. In comparison, last year the company earned a revenue of $20.66 million and had a GAAP net loss of $54.65 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.
Read More on HRTX:
- Heron Therapeutics: Craig Collard to succeed Barry Quart as CEO
- Heron Therapeutics Dives on Zynrelef Troubles
- Heron Therapeutics price target lowered to $10 from $15 at Evercore ISI
- Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates
- Heron Therapeutics reports Q4 EPS (17c), consensus (28c)
